Studies investigating a surrogate marker of BBB permeability, namely CSF/serum albumin ratio, have shown in Parkinson’s disease (Liguori et al., 2017), that this ratio increases with disease severity along with amyloid beta (Aβ) and total tau. The gene discussed is MAPT; the disease is Parkinson disease.